clinical research

Pancreatic

Back to Oncology/Cancer Clinical Trials Main Page

CPMC Cancer Services


Principal Investigator/Contact Information Protocol Title Patient Population Recruitment Period
Principal Investigator:
CPMC Oncologists

Contact:
Brenda Eng
415-600-1775
A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) + Gemcitabine + Erlotinib as 1st Line Treatment in Patients with Metastatic Pancreatic Cancer (SWOG 0727)
Visit this study on ClinicalTrials.gov.
Patients with pancreatic cancer that has spread to other parts of your body.Open
Principal Investigator:
Ari Baron, MD

Contact:
Rich Sommers
415-600-1578
A Phase II Study of Hyperacute®-Pancreatic Cancer Vaccine in subjects with surgically resected Pancreatic Cancer. NewLink Genetics NLG0205
Visit this study on ClinicalTrials.gov.
Subjects with Pancreatic Cancer Open



updated: 11/18/09


Back to top